BlackRock
ACTU

BlackRock’s Actuate Therapeutics ACTU Stock Holding History

BlackRock’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Sell
90,035
-337,118
-79% -$781K ﹤0.01% 4924
2026
Q1 		$1.17M Sell
427,153
-4,888
-1% -$20.3K ﹤0.01% 4283
2025
Q4 		$2.64M Buy
432,041
+149,967
+53% +$1.03M ﹤0.01% 4048
2025
Q3 		$1.89M Buy
282,074
+86,622
+44% +$628K ﹤0.01% 4110
2025
Q2 		$1.19M Buy
195,452
+187,854
+2,472% +$1.64M ﹤0.01% 4198
2025
Q1 		$51.4K Sell
7,598
-147
-2% -$1.18K ﹤0.01% 4919
2024
Q4 		$61.7K Buy
+7,745
New +$63.2K ﹤0.01% 4896

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM

BlackRock's ACTU Position: Q2 2026 in Review

BlackRock reduced its Actuate Therapeutics (ACTU) stake by 79% in Q2 2026, selling an estimated $781K and leaving 90,035 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #4924.

BlackRock first reported a position in ACTU in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.64M in Q4 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • BlackRock held 90,035 shares of Actuate Therapeutics worth $138K as of Q2 2026.
  • BlackRock sold 337,118 Actuate Therapeutics shares in Q2 2026, an estimated $781K.
  • Actuate Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4924 holding.
  • BlackRock first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BlackRock's Actuate Therapeutics position peaked at $2.64M in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.